Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer

Basit Öğe Kaydı
dc.contributor.authorKaya, Ali Osman
dc.contributor.authorBuyukberber, Suleyman
dc.contributor.authorDane, Faysal
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorUstaalioglu, Basak Oven
dc.contributor.authorCoskun, Ugur
dc.contributor.authorYumuk, Perran Fulden
dc.date.accessioned2024-04-24T17:33:20Z
dc.date.available2024-04-24T17:33:20Z
dc.date.issued2010
dc.departmentDicle Üniversitesien_US
dc.description.abstractAims. To evaluate activity and toxicity of cisplatin plus docetaxel combination in the first-line treatment of chemotherapy-naive patients with metastatic non-small cell lung cancer. Patients and methods. Between October 2004 and July 2008, 186 patients with metastatic non-small cell lung cancer treated with first-line cisplatin plus docetaxel were retrospectively evaluated in 7 centers. The chemotherapy schedule consisted of cisplatin, 75 mg/m(2) iv infusion, and docetaxel, 75 mg/m(2) iv infusion on day 1, every 3 weeks. Results. Median age was 56 years (range, 28-75). Eighteen patients (9.7%) were females and 168 (90.3%) were males, with a median ECOG performance status of 1 (range, 0-2). A total of 833 cycles of chemotherapy was administered (median, 4 cycles; range, 1-6). Two patients (1.1%) achieved clinical complete response, 77 patients (41.4%) partial response, and 66 patients (35.5%) stable disease. Median time to disease progression was 6 months (95% CI, 5.54-6.46). Median overall survival was 14.6 months (95% CI, 11.47-17.73). One- and 2-year overall survival was 55.2% and 19.7%, respectively. The most common grade 3-4 hematological toxicities were neutropenia (n = 32, 17.2%) and anemia (n = 4, 2.2%). Conclusions. The cisplatin plus docetaxel combination was effective and safe in the first-line treatment of patients with metastatic non-small cell lung cancer. Free full text available at www.tumorionline.iten_US
dc.identifier.endpage404en_US
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue3en_US
dc.identifier.pmid20845799
dc.identifier.scopus2-s2.0-77955006535
dc.identifier.scopusqualityQ3
dc.identifier.startpage400en_US
dc.identifier.urihttps://hdl.handle.net/11468/20627
dc.identifier.volume96en_US
dc.identifier.wosWOS:000287111100004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumori Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCisplatinen_US
dc.subjectDocetaxelen_US
dc.subjectMetastatic Non-Small Cell Lung Canceren_US
dc.titleCisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung canceren_US
dc.titleCisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu